OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • CME Opportunities
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Multidisciplinary Treatment of Advanced Soft Tissue Sarcomas

home / peer-exchange / soft-tissue-sarcoma
Incidence and Subtypes of Advanced Soft Tissue Sarcoma

EP. 1: Incidence and Subtypes of Advanced Soft Tissue Sarcoma

October 21st 2015
Accurately Diagnosing Soft Tissue Sarcoma

EP. 2: Accurately Diagnosing Soft Tissue Sarcoma

October 21st 2015
Multidisciplinary Assessment of Soft Tissue Sarcomas

EP. 3: Multidisciplinary Assessment of Soft Tissue Sarcomas

October 21st 2015
Implementation of Multidisciplinary Sarcoma Care

EP. 4: Implementation of Multidisciplinary Sarcoma Care

October 21st 2015
Key Members of the Multidisciplinary Team

EP. 5: Key Members of the Multidisciplinary Team

October 21st 2015
Integrating Community Oncologists Into the Multidisciplinary Team

EP. 6: Integrating Community Oncologists Into the Multidisciplinary Team

October 21st 2015
Importance of Surgery and Radiation in Advanced STS

EP. 7: Importance of Surgery and Radiation in Advanced STS

October 21st 2015
Chemotherapy Regimens for Advanced Soft Tissue Sarcoma

EP. 8: Chemotherapy Regimens for Advanced Soft Tissue Sarcoma

October 21st 2015
Chemotherapy Toxicity Considerations in Soft Tissue Sarcoma

EP. 9: Chemotherapy Toxicity Considerations in Soft Tissue Sarcoma

October 21st 2015
Subtyping in Soft Tissue Sarcoma: The PALLETTE Study

EP. 10: Subtyping in Soft Tissue Sarcoma: The PALLETTE Study

October 21st 2015
Use of Trabectedin in Soft Tissue Sarcoma

EP. 11: Use of Trabectedin in Soft Tissue Sarcoma

October 21st 2015
Patient Selection in Soft Tissue Sarcoma

EP. 12: Patient Selection in Soft Tissue Sarcoma

October 21st 2015
Early Data With Olaratumab in Soft Tissue Sarcoma

EP. 13: Early Data With Olaratumab in Soft Tissue Sarcoma

October 21st 2015
Phase III Data on Eribulin in Advanced STS

EP. 14: Phase III Data on Eribulin in Advanced STS

October 21st 2015
Future Directions in Soft Tissue Sarcoma

EP. 15: Future Directions in Soft Tissue Sarcoma

October 21st 2015

Latest Conference Coverage

Ribociclib/Endocrine Therapy Yields Similar pCRs Compared With Chemotherapy in HR+ Early Breast Cancer

Emiltatug Ledadotin Shows Early Clinical Activity and Safety in Advanced/Metastatic TNBC

Puxitatug Samrotecan Yields Responses With Manageable Safety in Pretreated HR+/HER2– Advanced Breast Cancer

Adjuvant Pertuzumab Plus Trastuzumab and Chemotherapy Leads to OS Benefit in Early-Stage HER2+ Breast Cancer

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact